Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafluprost/timolol - Santen Pharmaceutical

Next Previous
Drug Profile

Tafluprost/timolol - Santen Pharmaceutical

Alternative Names: DE-111; DE-111A; STN-10111; STN-1011101; Tafluprost/timolol maleate; TAPCOM; Tapcom-S; Taptiqom; Timolol maleate/tafluprost; Timolol/tafluprost

Latest Information Update: 15 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santen Oy; Santen Pharmaceutical
  • Developer AGC Biologics; Asahi Glass; Santen Oy; Santen Pharmaceutical
  • Class Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
  • Mechanism of Action Beta adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Sep 2025 Launched for Glaucoma in China (Ophthalmic)
  • 01 Sep 2025 Launched for Ocular hypertension in China (Ophthalmic)
  • 04 Apr 2023 Santen Pharmaceutical completes a phase-III clinical trial in Glaucoma in China (Ophthalmic) (NCT03822559)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top